Viventia Biotech, Inc. and Dowpharma contract manufacturing services, a business unit of The Dow Chemical Co., have entered into a commercial license agreement for Pfenex Expression Technology, a Pseudomonas-based technology from Dowpharma. Under the terms of the agreement, Viventia will employ Pfenex Expression Technology for as many as six therapeutic compounds, the first of which is an antibody-based product candidate in preclinical development. Pfenex Expression Technology accelerates speed ...